,

P-21

$125.00

Buy P-21 Peptide Online

P-21 (P021) is an experimental nootropic peptide designed from a region of the neural cell adhesion molecule (NCAM). It has attracted attention because animal research suggests potential effects on memory, synaptic plasticity, and neurodegenerative processes.

Product Information

P-21 is an adamantane-containing peptide derivative associated with NCAM-related signaling. The compound is particularly interesting because NCAM is involved in neuronal development, synaptic plasticity, and memory formation.

P-21 should not be confused with p21/CDKN1A, the well-known cell-cycle regulatory protein.

How Does It Work?

P-21 is designed to influence NCAM-related signaling and neuronal plasticity, potentially supporting synaptic function and memory-related pathways.

Benefits

Memory Research

Preclinical studies of P-21 have reported improvements in learning and memory in animal models, making it a prominent experimental peptide in cognitive research.

Neurodegeneration Research

P-21 has been investigated in models relevant to Alzheimer’s disease, particularly those involving amyloid-related neuronal dysfunction.

Synaptic Plasticity

The peptide’s connection with NCAM signaling makes it relevant to research into synaptic remodeling, neuronal connectivity, and learning.

Neuroprotective Research

Animal research has explored P-21 in relation to neuronal survival and restoration of cognitive performance following neurodegenerative insults.

Side Effects

Human safety data are extremely limited. Online reports mention headache, fatigue, nausea, dizziness, and sleep changes, but these should not be considered a validated safety profile.

Dosage

Community protocols commonly report approximately 100–500 mcg per administration, generally using intranasal or subcutaneous routes. These are experimental-use figures rather than doses established through human clinical trials.

Research References

Subramaniam S, et al. Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound. Journal of Alzheimer’s Disease. 2017. PMID: 28655344.

PubMed – Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound

Purerawz Disclaimer

Purerawz does not sell, manufacture, stock, dispense, or directly supply any of the products discussed on this website. Purerawz is an independent information and affiliate platform. Where available, links may direct readers to independent third-party providers, and Purerawz may receive a commission from qualifying purchases at no additional cost to the reader.

The information provided is for educational and informational purposes only. Dosage figures may reflect published research protocols, historical clinical use, or reported community practices and should not be interpreted as personalized medical instructions. Research findings—particularly those from animal, cellular, or small early-stage studies—do not establish that a product is safe or effective for every individual or condition.